RHHBY Roche Holding Ltd ADR (Sponsored)

31.09
-0.81  -3%
Previous Close 31.9
Open 31.27
Price To Book 7.71
Market Cap 212450049584
Shares 6,833,388,536
Volume 5,096,152
Short Ratio
Av. Daily Volume 1,334,436

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial initiated 3Q 2017.
IMspire170 - cobimetinib and atezolizumab
First-line BRAF wild-type metastatic or unresectable locally advanced melanoma
Phase 3 data released May 10, 2018. Primary endpoint not met.
IMblaze370 - cobimetinib and atezolizumab
Third-line advanced or metastatic colorectal cancer
Approval announced June 11, 2018.
Venclexta (MURANO)
Relapsed or refractory Chronic Lymphocytic Leukemia (CLL)
Phase 3 data due in 2019.
Kadcyla (KAITLIN)
HER2-positive breast cancer - adjuvant use
Phase 3 data released October 15, 2018 met primary endpoint. Data released December 5, 2018 noted HR = 0.50 (reduction of the risk of disease recurrence or death by 50%).
Kadcyla (KATHERINE).
HER2-positive breast cancer - residual invasive disease
Phase 3 PFS endpoint met - PFS=6.3 vs. 5.6 months for chemo. HR 0.71.
Tecentriq+cb+pac/nab-pac - IMpower131
Squamous non-small cell lung cancer (NSCLC)
FDA Approval announced December 6, 2018.
Tecentriq + Avastin - IMpower150
Non-squamous non-small cell lung cancer (NSCLC)
PFS endpoint met. HR 0.74 - February 6, 2018.
TECENTRIQ (atezolizumab) - IMmotion151
Kidney cancer - renal cell carcinoma (mRCC)
Approval announced June 7, 2018.
MabThera/ Rituxan (rituximab)
Pemphigus vulgaris
Phase 3 data released July 19, 2018. PFS endpoint met, OS endpoint not yet met - final OS data due 2019.
TECENTRIQ (atezolizumab) plus chemotherapy (carboplatin and Abraxane) - IMpower132
Squamous non-small cell lung cancer (NSCLC)
PDUFA date under priority review March 18, 2019.
Tecentriq+cb+etoposide - IMpower133
Squamous non-small cell lung cancer (NSCLC)
Phase 3 data released July 1, 2018. PFS endpoint met. PFS =7.2 vs. 5.5 months. HR 0.80.
Tecentriq plus nab-paclitaxe - IMpassion 130
First-line triple negative breast cancer (TNBC)
Phase 3 data released May 29, 2018. Primary endpoint met.
TECENTRIQ (atezolizumab) plus chemotherapy (carboplatin and Abraxane) - IMpower130
Squamous non-small cell lung cancer (NSCLC)
FDA Approval announced October 4, 2018.
Hemlibra
Hemophilia
Phase 3 updated data released at ASCO June 2018.
Alecensa - ALEX
Anaplastic lymphoma kinase (ALK)-positive metastatic (advanced) non-small cell lung cancer (NSCLC)
Phase 1b trial expansion announced June 1, 2018.
Cabozantinib + atezolizumab (TECENTRIQ) COSMIC-021
Solid tumors
FDA approval announced June 13, 2018.
Avastin (bevacizumab) + chemo
Ovarian cancer
Phase 3 enrollment has commenced - noted June 14, 2018.
Gantenerumab
Early Alzheimer's disease
PDUFA date under priority review December 24, 2018.
Baloxavir marboxil
Influenza
Phase 3 trial initiation announced July 26, 2018.
Subcutaneous Pertuzumab And Trastuzumab
HER2-positive early breast cancer
FDA approval announced November 21, 2018.
Venclexta
First line unfit AML

Latest News

  1. FDA approves Celltrion's biosimilar to Roche's Herceptin
  2. Pfizer's cut-price version of Avastin wins EU panel greenlight
  3. 5 Drug/Biotech Stocks With Promise to Sustain Bull Run in 2019
  4. Pharma Stock Roundup: AZN, RHHBY Cancer Drugs, LLY, BMY New Deals in Focus
  5. Roche to Create Companion Diagnostic Test for Merck's Keytruda
  6. Gilead Sciences (GILD) Appoints Daniel O'Day as New CEO
  7. New Gilead Sciences CEO Has 'Breadth Of Experience' From Time At Roche, Says Bullish Raymond James
  8. Roche to develop companion diagnostic test to help identify patients eligible for anti-PD-1 therapy based on biomarker expression, not location, of solid tumors
  9. [$$] Roche Taps Genentech Chief to Lead Pharmaceuticals Division
  10. Gilead: What New CEO Brings-and Doesn't--to the Table
  11. Gilead Sciences Names Roche's O'Day as CEO and Chairman
  12. Gilead Needs More Than a Steady Hand From Its New CEO
  13. Roche's Tecentriq Gets FDA Approval for First-Line NSCLC
  14. Gilead’s New CEO Might Boost Its Stock—Just Not Today
  15. Don’t Punish Gilead Stock for Doing Its Job
  16. Amgen (AMGN) Continues to Reward Shareholders, Ups Dividend
  17. Gilead Sciences snares Roche veteran O'Day as CEO
  18. [$$] US drugmaker Gilead poaches Roche executive Daniel O’Day
  19. New member proposed for election to Roche Board of Directors